MLH1, MSH2, MSH6, PMS2, or EPCAM Gene Mutations | mySupport360

MLH1, MSH2, MSH6, PMS2, or EPCAM Gene Mutations

Lynch syndrome (LS)

MLH1, MSH2, MSH6, PMS2, and EPCAM Associated Cancer Risks
BREAST OVARIAN GASTRIC COLORECTAL PANCREATIC MELANOMA PROSTATE ENDOMETRIAL OTHER

What does it mean to have a diagnosis of Lynch syndrome?

Lynch syndrome (LS) is caused by mutations in one of five genes: MLH1, MSH2, MSH6, PMS2, and EPCAM. LS is sometimes referred to as Hereditary Non-Polyposis Colorectal Cancer (HNPCC). People with LS have a high risk for several different kinds of cancer. The highest cancer risks are for colorectal cancer in men and women and endometrial cancer in women. These cancers can develop at young ages, and some people with LS may be diagnosed with cancer two or more times during their lifetime. People with LS also have an increased risk for the following cancers: ovarian, stomach (gastric), small bowel, ureter/renal pelvis, pancreatic, hepatobiliary tract, brain and sebaceous gland.

The exact cancer risks and medical management guidelines for people with LS are different depending on the gene in which a mutation was identified. In most cases, cancer risks are higher for mutations in MLH1, MSH2 and EPCAM than for mutations in MSH6 and PMS2.


What can be done to protect people with LS from cancer?

The National Comprehensive Cancer Network (NCCN) provides recommendations for lowering the risk of cancer in men and women with LS. Some recommendations include starting screening at a younger age and completing screenings more often than typically recommended. For example, colonoscopies to check for colorectal cancer should begin at age 25 or younger and should be done every 1 to 2 years for individuals with mutations in genes associated with LS.

Since women with LS have a high risk for ovarian and endometrial cancer, they may consider surgery to remove their ovaries and/or uterus after they have finished having children.

Because people with LS are at a high risk for many different types of cancer that may be hard to detect, it is recommended that people with LS be cared for by healthcare professionals with experience treating this condition.

Additional details about LS, including information about the risks for different kinds of cancers, specific recommendations for medical care, and useful information for relatives of people who have a diagnosis of LS are available within our Support Organizations pages.

MLH1 gene

Associated Syndrome Name: Lynch syndrome/Hereditary Non-Polyposis Colorectal Cancer (HNPCC)

MLH1 Summary Cancer Risk Table

Cancer Genetic Cancer Risk
ColorectalHigh Risk
EndometrialHigh Risk
GastricHigh Risk
OvarianHigh Risk
PancreaticElevated Risk
ProstateElevated Risk
OtherHigh Risk

MLH1 gene Overview

Lynch syndrome 1, 2, 3, 4, 5, 6, 7, 8, 9
  • Individuals with mutations in MLH1 have a condition called Lynch syndrome. This condition is also known as Hereditary Non-Polyposis Colon Cancer (HNPCC).
  • Men and women with Lynch syndrome due to mutations in MLH1 have a high risk of developing colorectal cancer, often at young ages. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome.
  • Women with Lynch syndrome due to mutations in MLH1 have a high risk for developing endometrial and ovarian cancer, often at young ages.
  • Patients with Lynch syndrome due to mutations in MLH1 also have an increased risk of developing a wide variety of other cancers, including gastric, small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, and pancreatic. These risks may be more significant in patients with a family history of these cancers. Therefore, the general screening and management recommendations provided below should be modified based on individualized risk assessment and counseling.
  • An increased risk for prostate cancer has been documented in multiple studies of men with Lynch syndrome. Estimates range from an approximately 2 to 5-fold increase in risk, but the exact increase has not yet been established for men with mutations in MLH1.
  • Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers.
  • Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and a high risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites.
  • Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network (NCCN) and other expert groups. These are listed below. It is recommended that patients with an MLH1 mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition.

MLH1 gene Cancer Risk Table

Cancer Type Age Range Cancer Risk Risk for General Population 10
ColorectalTo age 701, 652%-82%1.8%
EndometrialTo age 701, 625%-60%1.7%
Overall cancer risk (Lynch cancers)Risk for a second Lynch-related cancer after a first cancer diagnosis11, 12Increased riskNA
OvarianTo age 701, 64%-12%0.7%
GastricTo age 701, 66%-13%0.4%
Small BowelTo age 701, 63%-6%0.1%
Urinary TractTo age 701, 6, 81%-7%0.7%
PancreaticTo age 701, 2, 61%-6%0.5%
Hepatobiliary TractTo age 701, 61.4%-4%0.5%
Central Nervous SystemTo age 701, 61%-3%0.4%
Sebaceous NeoplasmsTo age 701, 61%-9%<1.0%
ProstateTo age 805, 6, 9Elevated Risk10.9%

MLH1 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

Cancer Type Procedure Age to Begin Frequency
ColorectalColonoscopy6, 720 to 25 years, or 2 to 5 years younger than the earliest diagnosis in family if it is under age 25Every 1 to 2 years
Colorectal surgical evaluation may be appropriate for some patients6IndividualizedNA
Consider the use of aspirin as a risk-reduction agent6, 7IndividualizedIndividualized
EndometrialPatient education about endometrial cancer symptoms.6IndividualizedNA
Consider pelvic examination, endometrial sampling and transvaginal ultrasound.6, 730 to 35 yearsAnnually
Consider hysterectomy.6, 7After completion of childbearingNA
OvarianConsider bilateral salpingo-oophorectomy.6, 7Age 40 or after completion of childbearingNA
Consider transvaginal ultrasound and CA-125 measurement.6, 730 to 35 yearsNA
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).6, 14IndividualizedNA
Patient education about ovarian cancer symptoms6IndividualizedNA
GastricConsider testing and treating Helicobacter pylori infection.7IndividualizedNA
Consider upper endoscopy, particularly for patients with additional risk factors for gastric cancer, such as family history or Asian ancestry. Consider biopsy of the antrum.6, 7, 1530 to 35 yearsEvery 2 to 5 years
Small BowelConsider upper endoscopy, particularly for patients with additional risk factors for small bowel cancer, such as family history.6, 730 to 35 yearsEvery 3 to 5 years
Urinary TractConsider urinalysis.6, 730 to 35 yearsAnnually
PancreaticFor patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols.16IndividualizedNA
Hepatobiliary TractCurrently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation carriers.6NANA
Central Nervous SystemPhysical/neurological examination625 to 30 yearsAnnually
Sebaceous NeoplasmsCurrently there are no specific medical management guidelines for sebaceous neoplasm risk in mutation carriers.NANA
ProstateCurrently there are no specific medical management guidelines for prostate cancer risk in mutation carriers. However, the possibility of an increased risk for prostate cancer can be incorporated into the risk and benefit discussion about offering screening with digital rectal examination (DRE) and Prostate Specific Antigen (PSA).1345 years, or youngerIndividualized

Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the MLH1 gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

In rare instances, an individual may inherit mutations in both copies of the MLH1 gene, leading to the condition Constitutional Mismatch Repair-Deficiency syndrome (CMMR-D). Individuals with CMMR-D often have significant complications in childhood, including colorectal polyposis and a high risk for colorectal, small bowel, brain, and hematologic cancers. Individuals with CMMR-D often have café-au-lait spots. The children of this patient are at risk of inheriting CMMR-D only if the other parent is also a carrier of a MLH1 mutation. Screening the spouse/partner of this patient for MLH1 mutations may be appropriate.1

References

  1. Kohlmann W, Gruber SB. Lynch Syndrome. 2014 May 22. In:Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ PMID: 20301390.
  2. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 302:1790-5. PMID: 19861671.
  3. Lin KM, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998 41:428-33. PMID: 9559626.
  4. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 105:274-9. PMID: 23385444.
  5. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 104:1363-72. PMID: 22933731.
  6. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2017. June 5. Available at http://www.nccn.org.
  7. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID: 25070057.
  8. Joost P, et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology. 2015 86:1212-7. PMID: 26385421.
  9. Ryan S, et al. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 23:437-49. PMID: 24425144.
  10. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
  11. Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. 2015 Dec 3. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK1469/ PMID: 20301642.
  12. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2016. October 20. Available at http://www.nccn.org.
  13. Carroll PR et al. NCCN Clinical Practice Guidelines in Oncology®: Prostate Cancer Early Detection. V 1.2017. June 5. Available at http://www.nccn.org.
  14. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V 2.2017. December 7. Available at http://www.nccn.org.
  15. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 1.2017. March 21. Available at http://www.nccn.org.
  16. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 62:339-47. PMID: 23135763.
Last Updated on 31-Aug-2017

MSH2 gene

Associated Syndrome Name: Lynch syndrome/Hereditary Non-Polyposis Colorectal Cancer (HNPCC)

MSH2 Summary Cancer Risk Table

Cancer Genetic Cancer Risk
ColorectalHigh Risk
EndometrialHigh Risk
GastricHigh Risk
OvarianHigh Risk
PancreaticElevated Risk
ProstateElevated Risk
OtherHigh Risk

MSH2 gene Overview

Lynch syndrome 1, 2, 3, 4, 5, 6, 7, 8, 9
  • Individuals with mutations in MSH2 have a condition called Lynch syndrome. This condition is also known as Hereditary Non-Polyposis Colon Cancer (HNPCC).
  • Men and women with Lynch syndrome due to mutations in MSH2 have a high risk of developing colorectal cancer, often at young ages. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome.
  • Women with Lynch syndrome due to mutations in MSH2 have a high risk for developing endometrial and ovarian cancer, often at young ages.
  • Patients with Lynch syndrome due to mutations in MSH2 also have an increased risk of developing a wide variety of other cancers, including gastric, small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, and pancreatic. These risks may be more significant in patients with a family history of these cancers. Therefore, the general screening and management recommendations provided below should be modified based on individualized risk assessment and counseling.
  • An increased risk for prostate cancer has been documented in multiple studies of men with Lynch syndrome. Estimates range from an approximately 2 to 5-fold increase in risk, but the exact increase has not yet been established for men with mutations in MSH2.
  • Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers.
  • Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and a high risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites.
  • Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network (NCCN) and other expert groups. These are listed below. It is recommended that patients with an MSH2 mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition.

MSH2 gene Cancer Risk Table

Cancer Type Age Range Cancer Risk Risk for General Population 10
ColorectalTo age 701, 652%-82%1.8%
EndometrialTo age 701, 625%-60%1.7%
Overall cancer risk (Lynch cancers)Risk for a second Lynch-related cancer after a first cancer diagnosis11, 12Increased riskNA
OvarianTo age 701, 64%-12%0.7%
GastricTo age 701, 66%-13%0.4%
Small BowelTo age 701, 63%-6%0.1%
Urinary TractTo age 701, 6, 81%-7%, or higher0.7%
PancreaticTo age 701, 2, 61%-6%0.5%
Hepatobiliary TractTo age 701, 61.4%-4%0.5%
Central Nervous SystemTo age 701, 61%-3%0.4%
Sebaceous NeoplasmsTo age 701, 61%-9%<1.0%
ProstateTo age 805, 6, 9Elevated Risk10.9%

MSH2 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

Cancer Type Procedure Age to Begin Frequency
ColorectalColonoscopy6, 720 to 25 years, or 2 to 5 years younger than the earliest diagnosis in family if it is under age 25Every 1 to 2 years
Colorectal surgical evaluation may be appropriate for some patients6IndividualizedNA
Consider the use of aspirin as a risk-reduction agent6, 7IndividualizedIndividualized
EndometrialPatient education about endometrial cancer symptoms.6IndividualizedNA
Consider pelvic examination, endometrial sampling and transvaginal ultrasound.6, 730 to 35 yearsAnnually
Consider hysterectomy.6, 7After completion of childbearingNA
OvarianConsider bilateral salpingo-oophorectomy.6, 7Age 40 or after completion of childbearingNA
Consider transvaginal ultrasound and CA-125 measurement.6, 730 to 35 yearsNA
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).6, 14IndividualizedNA
Patient education about ovarian cancer symptoms6IndividualizedNA
GastricConsider testing and treating Helicobacter pylori infection.7IndividualizedNA
Consider upper endoscopy, particularly for patients with additional risk factors for gastric cancer, such as family history or Asian ancestry. Consider biopsy of the antrum.6, 7, 1530 to 35 yearsEvery 2 to 5 years
Small BowelConsider upper endoscopy, particularly for patients with additional risk factors for small bowel cancer, such as family history.6, 730 to 35 yearsEvery 3 to 5 years
Urinary TractConsider urinalysis.6, 730 to 35 yearsAnnually
PancreaticFor patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols.16IndividualizedNA
Hepatobiliary TractCurrently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation carriers.6NANA
Central Nervous SystemPhysical/neurological examination625 to 30 yearsAnnually
Sebaceous NeoplasmsCurrently there are no specific medical management guidelines for sebaceous neoplasm risk in mutation carriers.NANA
ProstateCurrently there are no specific medical management guidelines for prostate cancer risk in mutation carriers. However, the possibility of an increased risk for prostate cancer can be incorporated into the risk and benefit discussion about offering screening with digital rectal examination (DRE) and Prostate Specific Antigen (PSA).1345 years, or youngerIndividualized

Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the MSH2 gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

In rare instances, an individual may inherit mutations in both copies of the MSH2 gene, leading to the condition Constitutional Mismatch Repair-Deficiency syndrome (CMMR-D). Individuals with CMMR-D often have significant complications in childhood, including colorectal polyposis and a high risk for colorectal, small bowel, brain, and hematologic cancers. Individuals with CMMR-D often have café-au-lait spots. The children of this patient are at risk of inheriting CMMR-D only if the other parent is also a carrier of a MSH2 mutation. Screening the spouse/partner of this patient for MSH2 mutations may be appropriate.1

References

  1. Kohlmann W, Gruber SB. Lynch Syndrome. 2014 May 22. In:Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ PMID: 20301390.
  2. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 302:1790-5. PMID: 19861671.
  3. Lin KM, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998 41:428-33. PMID: 9559626.
  4. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 105:274-9. PMID: 23385444.
  5. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 104:1363-72. PMID: 22933731.
  6. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2017. June 5. Available at http://www.nccn.org.
  7. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID: 25070057.
  8. Joost P, et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology. 2015 86:1212-7. PMID: 26385421.
  9. Ryan S, et al. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 23:437-49. PMID: 24425144.
  10. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
  11. Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. 2015 Dec 3. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK1469/ PMID: 20301642.
  12. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2016. October 20. Available at http://www.nccn.org.
  13. Carroll PR et al. NCCN Clinical Practice Guidelines in Oncology®: Prostate Cancer Early Detection. V 1.2017. June 5. Available at http://www.nccn.org.
  14. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V 2.2017. December 7. Available at http://www.nccn.org.
  15. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 1.2017. March 21. Available at http://www.nccn.org.
  16. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 62:339-47. PMID: 23135763.
Last Updated on 31-Aug-2017

MSH6 gene

Associated Syndrome Name: Lynch syndrome/Hereditary Non-Polyposis Colorectal Cancer (HNPCC)

MSH6 Summary Cancer Risk Table

Cancer Genetic Cancer Risk
ColorectalHigh Risk
EndometrialHigh Risk
PancreaticElevated Risk
GastricElevated Risk
OvarianElevated Risk
ProstateElevated Risk
OtherHigh Risk

MSH6 gene Overview

Lynch syndrome 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  • Individuals with mutations in MSH6 have a condition called Lynch syndrome. This condition is also known as Hereditary Non-Polyposis Colon Cancer (HNPCC).
  • Men and women with Lynch syndrome due to mutations in MSH6 have a high risk of developing colorectal cancer, often at younger ages than seen in the general population. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome. Colorectal cancer risk may be somewhat lower in women than in men, but there are no differences in the colorectal cancer screening guidelines for men and women.
  • Women with Lynch syndrome due to mutations in MSH6 have a high risk for developing endometrial cancer and an elevated risk for ovarian cancer, often at younger ages than typical in the general population.
  • Patients with Lynch syndrome due to mutations in MSH6 are also believed to have an increased risk of developing a wide variety of other Lynch syndrome associated cancers, including gastric, small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, and pancreatic. Precise risk estimates are not available because there is less information available for patients with MSH6 mutations compared with patients who have mutations in other Lynch syndrome genes. These risks may be more significant in patients with a family history of these cancers. Therefore, the general screening and management recommendations provided below should be modified based on individualized risk assessment and counseling.
  • An increased risk for prostate cancer has been documented in multiple studies of men with Lynch syndrome. Estimates range from an approximately 2 to 5-fold increase in risk, but the exact increase has not yet been established for men with mutations in MSH6.
  • Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers.
  • Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and an increased risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites.
  • Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network (NCCN) and other expert groups. These are listed below. It is recommended that patients with an MSH6 mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition.

MSH6 gene Cancer Risk Table

Cancer Type Age Range Cancer Risk Risk for General Population 11
Colorectal (male)To age 704, 5, 622%-69%2.0%
EndometrialTo age 704, 5, 616%-71%1.7%
Overall cancer risk (Lynch cancers)Risk for a second Lynch-related cancer after a first cancer diagnosis12, 13Increased riskNA
Colorectal (female)To age 704, 5, 610%-30%1.5%
OvarianTo age 701, 4, 5, 6, 8Elevated risk0.7%
GastricTo age 701, 4, 5, 6, 8Elevated risk0.4%
Small BowelTo age 701, 4, 5, 6, 8Elevated risk0.1%
Urinary TractTo age 701, 4, 5, 6, 8Elevated risk0.7%
PancreaticTo age 708, 14, 15Elevated risk0.5%
Hepatobiliary TractTo age 701, 4, 5, 6, 8Elevated risk0.5%
Central Nervous SystemTo age 701, 4, 5, 6, 8Elevated risk0.4%
Sebaceous NeoplasmsTo age 701, 4, 5, 6, 8Elevated risk<1.0%
ProstateTo age 807, 8, 10Elevated Risk10.9%

MSH6 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

Cancer Type Procedure Age to Begin Frequency
ColorectalColonoscopy8, 920 to 25 years, or 2 to 5 years younger than the earliest diagnosis in family if it is under age 25Every 1 to 2 years
Colorectal surgical evaluation may be appropriate for some patients8IndividualizedNA
Consider the use of aspirin as a risk-reduction agent8, 9IndividualizedIndividualized
EndometrialPatient education about endometrial cancer symptoms.8IndividualizedNA
Consider pelvic examination, endometrial sampling and transvaginal ultrasound.8, 930 to 35 yearsAnnually
Consider hysterectomy.8, 9After completion of childbearingNA
OvarianConsider bilateral salpingo-oophorectomy.8, 9Age 40 or after completion of childbearingNA
Consider transvaginal ultrasound and CA-125 measurement.8, 930 to 35 yearsNA
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).8, 17IndividualizedNA
Patient education about ovarian cancer symptoms8IndividualizedNA
GastricConsider testing and treating Helicobacter pylori infection.9IndividualizedNA
Consider upper endoscopy, particularly for patients with additional risk factors for gastric cancer, such as family history or Asian ancestry. Consider biopsy of the antrum.8, 9, 1830 to 35 yearsEvery 2 to 5 years
Small BowelConsider upper endoscopy, particularly for patients with additional risk factors for small bowel cancer, such as family history.8, 930 to 35 yearsEvery 3 to 5 years
Urinary TractConsider urinalysis.8, 930 to 35 yearsAnnually
PancreaticFor patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols.14IndividualizedNA
Hepatobiliary TractCurrently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation carriers.8NANA
Central Nervous SystemPhysical/neurological examination825 to 30 yearsAnnually
Sebaceous NeoplasmsCurrently there are no specific medical management guidelines for sebaceous neoplasm risk in mutation carriers.NANA
ProstateCurrently there are no specific medical management guidelines for prostate cancer risk in mutation carriers. However, the possibility of an increased risk for prostate cancer can be incorporated into the risk and benefit discussion about offering screening with digital rectal examination (DRE) and Prostate Specific Antigen (PSA).1645 years, or youngerIndividualized

Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the MSH6 gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

In rare instances, an individual may inherit mutations in both copies of the MSH6 gene, leading to the condition Constitutional Mismatch Repair-Deficiency syndrome (CMMR-D). Individuals with CMMR-D often have significant complications in childhood, including colorectal polyposis and a high risk for colorectal, small bowel, brain, and hematologic cancers. Individuals with CMMR-D often have café-au-lait spots. The children of this patient are at risk of inheriting CMMR-D only if the other parent is also a carrier of a MSH6 mutation. Screening the spouse/partner of this patient for MSH6 mutations may be appropriate.1

References

  1. Kohlmann W, Gruber SB. Lynch Syndrome. 2014 May 22. In:Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ PMID: 20301390.
  2. Lin KM, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998 41:428-33. PMID: 9559626.
  3. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 105:274-9. PMID: 23385444.
  4. Hendriks YM, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology. 2004 127:17-25. PMID: 15236168.
  5. Bonadona V, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011 305:2304-10. PMID: 21642682.
  6. Baglietto L, et al. Risks of Lynch syndrome cancers for MSH6 mutation carriers. J Natl Cancer Inst. 2010 102:193-201. PMID: 20028993.
  7. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 104:1363-72. PMID: 22933731.
  8. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2017. June 5. Available at http://www.nccn.org.
  9. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID: 25070057.
  10. Ryan S, et al. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 23:437-49. PMID: 24425144.
  11. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
  12. Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. 2015 Dec 3. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK1469/ PMID: 20301642.
  13. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2016. October 20. Available at http://www.nccn.org.
  14. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 62:339-47. PMID: 23135763.
  15. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 302:1790-5. PMID: 19861671.
  16. Carroll PR et al. NCCN Clinical Practice Guidelines in Oncology®: Prostate Cancer Early Detection. V 1.2017. June 5. Available at http://www.nccn.org.
  17. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V 2.2017. December 7. Available at http://www.nccn.org.
  18. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 1.2017. March 21. Available at http://www.nccn.org.
Last Updated on 31-Aug-2017

PMS2 gene

Associated Syndrome Name: Lynch syndrome/Hereditary Non-Polyposis Colorectal Cancer (HNPCC)

PMS2 Summary Cancer Risk Table

Cancer Genetic Cancer Risk
ColorectalHigh Risk
EndometrialHigh Risk
PancreaticElevated Risk
GastricElevated Risk
OvarianElevated Risk
ProstateElevated Risk
OtherHigh Risk

PMS2 gene Overview

Lynch syndrome 1, 2, 3, 4, 5, 6, 7, 8, 9
  • Individuals with mutations in PMS2 have a condition called Lynch syndrome. This condition is also known as Hereditary Non-Polyposis Colon Cancer (HNPCC).
  • Men and women with Lynch syndrome due to mutations in PMS2 have a high risk of developing colorectal cancer, often at younger ages than seen in the general population. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome.
  • Women with Lynch syndrome due to mutations in PMS2 have a high risk for developing endometrial cancer and possibly an elevated risk for ovarian cancer, often at younger ages than typical in the general population.
  • Patients with Lynch syndrome due to mutations in PMS2 are also believed to have an increased risk of developing a wide variety of other Lynch syndrome associated cancers, including gastric, small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, and pancreatic. Precise risk estimates are not available because there is less information available for patients with PMS2 mutations compared with patients who have mutations in other Lynch syndrome genes. These risks may be more significant in patients with a family history of these cancers. Therefore, the general screening and management recommendations provided below should be modified based on individualized risk assessment and counseling.
  • An increased risk for prostate cancer has been documented in multiple studies of men with Lynch syndrome. Estimates range from an approximately 2 to 5-fold increase in risk, but the exact increase has not yet been established for men with mutations in PMS2.
  • Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers.
  • Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and a high risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites.
  • Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network (NCCN) and other expert groups. These are listed below. It is recommended that patients with a PMS2 mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition.

PMS2 gene Cancer Risk Table

Cancer Type Age Range Cancer Risk Risk for General Population 10
ColorectalTo age 702, 11Up to 20%1.8%
EndometrialTo age 702, 11Up to 15%1.7%
Overall cancer risk (Lynch cancers)Risk for a second Lynch-related cancer after a first cancer diagnosis12, 13Increased riskNA
OvarianTo age 701, 2, 7, 11Elevated risk0.7%
GastricTo age 701, 2, 7, 11Elevated risk0.4%
Small BowelTo age 701, 2, 7, 11Elevated risk0.1%
Urinary TractTo age 701, 2, 7, 11Elevated risk0.7%
PancreaticTo age 701, 2, 3, 7, 11, 14Elevated risk0.5%
Hepatobiliary TractTo age 701, 2, 7, 11Elevated risk0.5%
Central Nervous SystemTo age 701, 2, 7, 11Elevated risk0.4%
Sebaceous NeoplasmsTo age 701, 2, 7, 11Elevated risk<1.0%
ProstateTo age 806, 7, 9Elevated Risk10.9%

PMS2 Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

Cancer Type Procedure Age to Begin Frequency
ColorectalColonoscopy7, 820 to 25 years, or 2 to 5 years younger than the earliest diagnosis in family if it is under age 25Every 1 to 2 years
Colorectal surgical evaluation may be appropriate for some patients7IndividualizedNA
Consider the use of aspirin as a risk-reduction agent7, 8IndividualizedIndividualized
EndometrialPatient education about endometrial cancer symptoms.7IndividualizedNA
Consider pelvic examination, endometrial sampling and transvaginal ultrasound.7, 830 to 35 yearsAnnually
Consider hysterectomy.7, 8After completion of childbearingNA
OvarianConsider bilateral salpingo-oophorectomy.7, 8Age 40 or after completion of childbearingNA
Consider transvaginal ultrasound and CA-125 measurement.7, 830 to 35 yearsNA
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).7, 16IndividualizedNA
Patient education about ovarian cancer symptoms7IndividualizedNA
GastricConsider testing and treating Helicobacter pylori infection.8IndividualizedNA
Consider upper endoscopy, particularly for patients with additional risk factors for gastric cancer, such as family history or Asian ancestry. Consider biopsy of the antrum.7, 8, 1730 to 35 yearsEvery 2 to 5 years
Small BowelConsider upper endoscopy, particularly for patients with additional risk factors for small bowel cancer, such as family history.7, 830 to 35 yearsEvery 3 to 5 years
Urinary TractConsider urinalysis.7, 830 to 35 yearsAnnually
PancreaticFor patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols.14IndividualizedNA
Hepatobiliary TractCurrently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation carriers.7NANA
Central Nervous SystemPhysical/neurological examination725 to 30 yearsAnnually
Sebaceous NeoplasmsCurrently there are no specific medical management guidelines for sebaceous neoplasm risk in mutation carriers.NANA
ProstateCurrently there are no specific medical management guidelines for prostate cancer risk in mutation carriers. However, the possibility of an increased risk for prostate cancer can be incorporated into the risk and benefit discussion about offering screening with digital rectal examination (DRE) and Prostate Specific Antigen (PSA).1545 years, or youngerIndividualized

Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the PMS2 gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

In rare instances, an individual may inherit mutations in both copies of the PMS2 gene, leading to the condition Constitutional Mismatch Repair-Deficiency syndrome (CMMR-D). Individuals with CMMR-D often have significant complications in childhood, including colorectal polyposis and a high risk for colorectal, small bowel, brain, and hematologic cancers. Individuals with CMMR-D often have café-au-lait spots. The children of this patient are at risk of inheriting CMMR-D only if the other parent is also a carrier of a PMS2 mutation. Screening the spouse/partner of this patient for PMS2 mutations may be appropriate.1

References

  1. Kohlmann W, Gruber SB. Lynch Syndrome. 2014 May 22. In:Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ PMID: 20301390.
  2. Senter L, et al. The clinical phenotype of Lynch syndrome due to germline PMS2 mutations. Gastroenterology. 2008 135419-28. PMID: 18602922.
  3. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 302:1790-5. PMID: 19861671.
  4. Lin KM, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998 41:428-33. PMID: 9559626.
  5. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 105:274-9. PMID: 23385444.
  6. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 104:1363-72. PMID: 22933731.
  7. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2017. June 5. Available at http://www.nccn.org.
  8. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID: 25070057.
  9. Ryan S, et al. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 23:437-49. PMID: 24425144.
  10. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
  11. ten Broeke SW, et al. Lynch syndrome caused by germline PMS2 mutations: delineating the cancer risk. J Clin Oncol. 2015 33:319-25. PMID: 25512458.
  12. Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. 2015 Dec 3. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK1469/ PMID: 20301642.
  13. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2016. October 20. Available at http://www.nccn.org.
  14. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 62:339-47. PMID: 23135763.
  15. Carroll PR et al. NCCN Clinical Practice Guidelines in Oncology®: Prostate Cancer Early Detection. V 1.2017. June 5. Available at http://www.nccn.org.
  16. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V 2.2017. December 7. Available at http://www.nccn.org.
  17. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 1.2017. March 21. Available at http://www.nccn.org.
Last Updated on 31-Aug-2017

EPCAM gene

Associated Syndrome Name: Lynch syndrome/Hereditary Non-Polyposis Colorectal Cancer (HNPCC)

EPCAM Summary Cancer Risk Table

Cancer Genetic Cancer Risk
ColorectalHigh Risk
EndometrialHigh Risk
GastricHigh Risk
OvarianHigh Risk
PancreaticElevated Risk
ProstateElevated Risk
OtherHigh Risk

EPCAM gene Overview

Lynch syndrome 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
  • Individuals with mutations in EPCAM have a condition called Lynch syndrome. This condition is also known as Hereditary Non-Polyposis Colon Cancer (HNPCC).
  • Men and women with Lynch syndrome due to mutations in EPCAM have a high risk of developing colorectal cancer, often at young ages. Colorectal cancer in patients with Lynch syndrome develops from adenomatous polyps which progress to cancer more quickly than polyps in individuals who do not have Lynch syndrome.
  • Women with Lynch syndrome due to mutations in EPCAM have a high risk for developing endometrial and ovarian cancer, often at young ages.
  • Patients with Lynch syndrome due to mutations in EPCAM are also believed to have an increased risk of developing a wide variety of other cancers, including gastric, small bowel, urinary tract, hepatobiliary tract, brain (usually glioblastoma), sebaceous gland, and pancreatic. These risks may be more significant in patients with a family history of these cancers. Therefore, the general screening and management recommendations provided below should be modified based on individualized risk assessment and counseling.
  • An increased risk for prostate cancer has been documented in multiple studies of men with Lynch syndrome. Estimates range from an approximately 2 to 5-fold increase in risk, but the exact increase has not yet been established for men with mutations in EPCAM.
  • Studies have investigated the possibility that patients with Lynch syndrome have an increased risk for other cancers, including breast cancer and adrenocortical carcinoma. However, the data are not conclusive at this time and there are currently no medical management guidelines related to these cancers.
  • Patients with Lynch syndrome have a high risk for developing second primary cancers following an initial diagnosis of colorectal or endometrial cancer. This includes a high risk for endometrial cancer in women following colorectal cancer and vice versa, a high risk for a second primary colorectal cancer in any portions of the colon or rectum remaining after surgical treatment, and a high risk for other Lynch associated cancers, such as those of the upper gastrointestinal tract, urinary tract, and other sites.
  • Cancer risks for patients with Lynch syndrome due to mutations in EPCAM are currently estimated to be similar to those for patients with Lynch syndrome due to mutations in MSH2, and medical management guidelines are currently the same for patients with mutations in either gene. However, it is possible that this will change over time as we learn more about the exact risks associated with mutations in EPCAM. There are some early indications that endometrial cancer risk may be much lower for women with certain types of mutations in EPCAM.
  • Although there are high risks for cancer in patients with Lynch syndrome, many of these risks can be greatly reduced with appropriate medical management. Guidelines for the medical management of patients with Lynch syndrome have been developed by the National Comprehensive Cancer Network (NCCN) and other expert groups. These are listed below. It is recommended that patients with an EPCAM mutation and a diagnosis of Lynch syndrome be managed by a multidisciplinary team with expertise in medical genetics and the care of patients with this condition.

EPCAM gene Cancer Risk Table

Cancer Type Age Range Cancer Risk Risk for General Population 11
ColorectalTo age 701, 752%-82%1.8%
EndometrialTo age 701, 725%-60%1.7%
Overall cancer risk (Lynch cancers)Risk for a second Lynch-related cancer after a first cancer diagnosis12, 13Increased riskNA
OvarianTo age 701, 74%-12%0.7%
GastricTo age 701, 76%-13%0.4%
Small BowelTo age 701, 73%-6%0.1%
Urinary TractTo age 701, 7, 91%-7%, or higher0.7%
PancreaticTo age 701, 2, 71%-6%0.5%
Hepatobiliary TractTo age 701, 71.4%-4%0.5%
Central Nervous SystemTo age 701, 71%-3%0.4%
Sebaceous NeoplasmsTo age 701, 71%-9%<1.0%
ProstateTo age 805, 7, 10Elevated Risk10.9%

EPCAM Cancer Risk Management Table

The overview of medical management options provided is a summary of professional society guidelines as of the last Myriad update shown on this page. The specific reference provided (e.g., NCCN guidelines) should be consulted for more details and up-to-date information before developing a treatment plan for a particular patient.

This overview is provided for informational purposes only and does not constitute a recommendation. While the medical society guidelines summarized herein provide important and useful information, medical management decisions for any particular patient should be made in consultation between that patient and his or her healthcare provider and may differ from society guidelines based on a complete understanding of the patient’s personal medical history, surgeries and other treatments.

Cancer Type Procedure Age to Begin Frequency
ColorectalColonoscopy7, 820 to 25 years, or 2 to 5 years younger than the earliest diagnosis in family if it is under age 25Every 1 to 2 years
Colorectal surgical evaluation may be appropriate for some patients7IndividualizedNA
Consider the use of aspirin as a risk-reduction agent7, 8IndividualizedIndividualized
EndometrialPatient education about endometrial cancer symptoms.7IndividualizedNA
Consider pelvic examination, endometrial sampling and transvaginal ultrasound.7, 830 to 35 yearsAnnually
Consider hysterectomy.7, 8After completion of childbearingNA
OvarianConsider bilateral salpingo-oophorectomy.7, 8Age 40 or after completion of childbearingNA
Consider transvaginal ultrasound and CA-125 measurement.7, 830 to 35 yearsNA
Consider options for ovarian cancer risk-reduction agents (i.e. oral contraceptives).7, 15IndividualizedNA
Patient education about ovarian cancer symptoms7IndividualizedNA
GastricConsider testing and treating Helicobacter pylori infection.8IndividualizedNA
Consider upper endoscopy, particularly for patients with additional risk factors for gastric cancer, such as family history or Asian ancestry. Consider biopsy of the antrum.7, 8, 1630 to 35 yearsEvery 2 to 5 years
Small BowelConsider upper endoscopy, particularly for patients with additional risk factors for small bowel cancer, such as family history.7, 830 to 35 yearsEvery 3 to 5 years
Urinary TractConsider urinalysis.7, 830 to 35 yearsAnnually
PancreaticFor patients with a family history of pancreatic cancer, consider available options for pancreatic cancer screening, including the possibility of endoscopic ultrasonography (EUS) and MRI/magnetic resonance cholangiopancreatography (MRCP). It is recommended that patients who are candidates for pancreatic cancer screening be managed by a multidisciplinary team with experience in the screening for pancreatic cancer, preferably within research protocols.17IndividualizedNA
Hepatobiliary TractCurrently there are no specific medical management guidelines for hepatobiliary cancer risk in mutation carriers.7NANA
Central Nervous SystemPhysical/neurological examination725 to 30 yearsAnnually
Sebaceous NeoplasmsCurrently there are no specific medical management guidelines for sebaceous neoplasm risk in mutation carriers.NANA
ProstateCurrently there are no specific medical management guidelines for prostate cancer risk in mutation carriers. However, the possibility of an increased risk for prostate cancer can be incorporated into the risk and benefit discussion about offering screening with digital rectal examination (DRE) and Prostate Specific Antigen (PSA).1445 years, or youngerIndividualized

Information for Family Members

The following information for Family Members will appear as part of the MMT for a patient found to have a mutation in the EPCAM gene.

A major potential benefit of myRisk genetic testing for hereditary cancer risk is the opportunity to prevent cancer in relatives of patients in whom clinically significant mutations are identified. Healthcare providers have an important role in making sure that patients with clinically significant mutations are informed about the risks to relatives, and ways in which genetic testing can guide lifesaving interventions.

References

  1. Kohlmann W, Gruber SB. Lynch Syndrome. 2014 May 22. In:Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2014. Available from http://www.ncbi.nlm.nih.gov/books/NBK1211/ PMID: 20301390.
  2. Kastrinos F, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009 302:1790-5. PMID: 19861671.
  3. Lin KM, et al. Colorectal and extracolonic cancer variations in MLH1/MSH2 hereditary nonpolyposis colorectal cancer kindreds and the general population. Dis Colon Rectum. 1998 41:428-33. PMID: 9559626.
  4. Win AK, et al. Risks of colorectal and other cancers after endometrial cancer for women with Lynch syndrome. J Natl Cancer Inst. 2013 105:274-9. PMID: 23385444.
  5. Win AK, et al. Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. J Natl Cancer Inst. 2012 104:1363-72. PMID: 22933731.
  6. Kempers MJ, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet. Oncol. 2011 12:49-55. PMID: 21145788.
  7. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Genetic/Familial High-Risk Assessment: Colorectal. V 1.2017. June 5. Available at http://www.nccn.org.
  8. Giardiello FM, et al. Guidelines on Genetic Evaluation and Management of Lynch Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 109:1159-79. PMID: 25070057.
  9. Joost P, et al. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology. 2015 86:1212-7. PMID: 26385421.
  10. Ryan S, et al. Risk of prostate cancer in Lynch syndrome: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 23:437-49. PMID: 24425144.
  11. Fast Stats: An interactive tool for access to SEER cancer statistics. Surveillance Research Program, National Cancer Institute. https://seer.cancer.gov/faststats. (Accessed on 1-2-2017)
  12. Larsen Haidle J, Howe JR. Juvenile Polyposis Syndrome. 2015 Dec 3. In: Pagon RA, et al., editors. GeneReviews® [Internet]. Available from http://www.ncbi.nlm.nih.gov/books/NBK1469/ PMID: 20301642.
  13. Provenzale D, et al. NCCN Clinical Practice Guidelines in Oncology® Colorectal Cancer Screening. V 2.2016. October 20. Available at http://www.nccn.org.
  14. Carroll PR et al. NCCN Clinical Practice Guidelines in Oncology®: Prostate Cancer Early Detection. V 1.2017. June 5. Available at http://www.nccn.org.
  15. Daly M et al. NCCN Clinical Practice Guidelines in Oncology®: Genetic/Familial High-Risk Assessment: Breast and Ovarian. V 2.2017. December 7. Available at http://www.nccn.org.
  16. Ajani JA, et al. NCCN Clinical Practice Guidelines in Oncology®: Gastric Cancer. V 1.2017. March 21. Available at http://www.nccn.org.
  17. Canto MI, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013 62:339-47. PMID: 23135763.
Last Updated on 31-Aug-2017
""